NCT03637543View on ClinicalTrials.gov

Nivolumab in Patients With High-Risk Biochemically Recurrent Prostate Cancer

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

31

Participants

Timeline

Start Date

October 18, 2018

Primary Completion Date

September 30, 2023

Study Completion Date

December 31, 2026

Conditions
Prostate Cancer
Interventions
DRUG

Nivolumab

Nivolumab is an antibody inhibitor of the programmed death-1 (PD-1) pathway. By blocking PD-1, this medication may allow the immune system to recognize and fight cancer

Trial Locations (5)

02135

St. Elizabeth's Medical Center, Boston

02215

Beth Israel Deaconess Medical Center, Boston

Dana Farber Cancer Institute, Boston

02190

DFCI South Shore, South Weymouth

03053

DFCI Londonderry, Londonderry

Sponsors

Collaborators (1)

Bristol-Myers Squibb
All Listed Sponsors
collaborator

Bristol-Myers Squibb

INDUSTRY

collaborator

Dana-Farber Cancer Institute

OTHER

lead

Beth Israel Deaconess Medical Center

OTHER

NCT03637543 - Nivolumab in Patients With High-Risk Biochemically Recurrent Prostate Cancer | Biotech Hunter | Biotech Hunter